First Multi-Center Study Combining the Allurion Program With GLP-1 Therapy Presented at the European Congress on Obesity
Combination therapy led to nearly 19% weight loss at approximately 8 months
Excerpt from the Press Release:
NATICK, Mass.–(BUSINESS WIRE)–Allurion, a company dedicated to ending obesity, today announced results from a new study that will be presented at the European Congress on Obesity exploring the use of a GLP-1 weight-loss medication with the Allurion Gastric Balloon Program to enhance patient outcomes.
The retrospective study was conducted across 3 obesity centers in Italy, Spain and Egypt. In total, 181 patients with BMIs of 27 and above were enrolled in the Allurion Program with Saxenda® (liraglutide) added once daily starting 4 to 16 weeks after balloon placement. On average, the duration of drug treatment was just over 4 months (4.1 ± 2.2 months).
All patients were followed for at least 6 months by a multidisciplinary team using digital monitoring tools, including the Allurion Connected Scale and app.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?